Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension

References

• Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243–78
   Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S–24
   Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–4
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–9
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860–8
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–7
   PubMed Web of Science ®Google Scholar
• Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001;20:262–3
   PubMedGoogle Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903
   PubMed Web of Science ®Google Scholar
• Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S–7
   Google Scholar
• Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 2003;35:605–13
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227–37
   Google Scholar
• Cheng JW. Bosentan. Heart Dis 2003;5:161–9
   PubMedGoogle Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119–23
   PubMed Web of Science ®Google Scholar
• Sitbon O, McLaughlin V, Badesch D, et al. Comparison of two treatment strategies, first-line bosentan or epoprostenol, on survival in class III idiopathic pulmonary arterial hypertension. Am J Resp Crit Care Med 2004;169:A210 [Abstract]
   Google Scholar
• Rosenzweig E, Ivy D, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. Am J Resp Crit Care Med 2004;169:A210 [Abstract]
   Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244–9
   PubMed Web of Science ®Google Scholar
• Keogh A, Macdonald P, William T, et al. Bosentan for the treatment of pulmonary arterial hypertension – 6 month quality of life data. JHLT 2004;23:S54 [Abstract]
   Google Scholar
• Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43:48S–55
   Google Scholar
• Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–92
   PubMed Web of Science ®Google Scholar
• Peacock A, Naeije R, Galie N, et al. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004;23: 947–53
   PubMed Web of Science ®Google Scholar
• Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991;18:1738–44
   PubMed Web of Science ®Google Scholar
• Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647–52
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001;37:110–1
   PubMedGoogle Scholar
• Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:509–13
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487–92
   PubMed Web of Science ®Google Scholar
• Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844–8
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Burnett Jr JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988–94
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43:55–60
   PubMed Web of Science ®Google Scholar
• Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003;97:1230–6
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003; 48:3503–8
   PubMed Web of Science ®Google Scholar
• American Thoracic Society Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002;166:111–7
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216–23
   PubMed Web of Science ®Google Scholar
• Ware Jr JE, Snow KK, Kosinski M. SF36: health survey manual and interpretation guide. Lincoln R, editor. Qualimetric Inc., 2000
   Google Scholar